March 6 Deadline Set for FRMI Securities Claims Following Tenant Agreement Collapse

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Fermi Inc. faces securities lawsuit after major tenant canceled $150M funding deal, causing 52% stock decline. Investors must file claims by March 6.

March 6 Deadline Set for FRMI Securities Claims Following Tenant Agreement Collapse

Fermi Inc. is the subject of a federal securities class action lawsuit stemming from allegations that the company issued materially misleading statements regarding tenant demand for its Project Matador campus development and misrepresented the status of committed funding. The litigation was initiated after a major tenant terminated a $150 million funding agreement in December 2025, prompting a significant equity decline.

Following the tenant agreement's termination, Fermi's stock price declined approximately 33% from its initial public offering price of $21 per share to $10.09, representing substantial losses for early investors. The decline reflects market repricing of the company's project viability and financial projections in light of the withdrawn funding commitment.

Investors who sustained losses of $75,000 or greater have until March 6, 2026 to assert their claims through counsel. The lawsuit seeks recovery for shareholders who purchased Fermi securities during the period when the company's public disclosures allegedly contained false or misleading information regarding the Project Matador initiative and its associated funding commitments.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 15

Related Coverage

GlobeNewswire Inc.

Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.

INO
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR